搜索结果：Drug development and industrial pharmacy

The role of Artificial Intelligence (AI) is growing in every stage of drug development. Nevertheless, a major challenge in drug discovery AI remains: Drug pharmacokinetic (PK) and Drug-Target Interaction (DTI) datasets collected in different studies often exhibit limited overlap, creating data overlap sparsity. Thus, data curation becomes difficult, negatively impacting downstream research investigations in high-throughput screening, polypharmacy, and drug combination. We propose xImagand-DKI, a novel SMILES/Protein-to-Pharmacokinetic/DTI (SP2PKDTI) diffusion model capable of generating an array of PK and DTI target properties conditioned on SMILES and protein inputs that exhibit data overlap sparsity. We infuse additional molecular and genomic domain knowledge from the Gene Ontology (GO) and molecular fingerprints to further improve our model performance. We show that xImagand-DKI-generated synthetic PK data closely resemble real data univariate and bivariate distributions, and can adequately fill in gaps among PK and DTI datasets. As such, xImagand-DKI is a promising solution for data overlap sparsity and may improve performance for downstream drug discovery research tasks. Code

Graph Machine Learning (GML) is receiving growing interest within the pharmaceutical and biotechnology industries for its ability to model biomolecular structures, the functional relationships between them, and integrate multi-omic datasets - amongst other data types. Herein, we present a multidisciplinary academic-industrial review of the topic within the context of drug discovery and development. After introducing key terms and modelling approaches, we move chronologically through the drug development pipeline to identify and summarise work incorporating: target identification, design of small molecules and biologics, and drug repurposing. Whilst the field is still emerging, key milestones including repurposed drugs entering in vivo studies, suggest graph machine learning will become a modelling framework of choice within biomedical machine learning.

To discover new drugs is to seek and to prove causality. As an emerging approach leveraging human knowledge and creativity, data, and machine intelligence, causal inference holds the promise of reducing cognitive bias and improving decision making in drug discovery. While it has been applied across the value chain, the concepts and practice of causal inference remain obscure to many practitioners. This article offers a non-technical introduction to causal inference, reviews its recent applications, and discusses opportunities and challenges of adopting the causal language in drug discovery and development.

The birth of ChatGPT, a cutting-edge language model-based chatbot developed by OpenAI, ushered in a new era in AI. However, due to potential pitfalls, its role in rigorous scientific research is not clear yet. This paper vividly showcases its innovative application within the field of drug discovery. Focused specifically on developing anti-cocaine addiction drugs, the study employs GPT-4 as a virtual guide, offering strategic and methodological insights to researchers working on generative models for drug candidates. The primary objective is to generate optimal drug-like molecules with desired properties. By leveraging the capabilities of ChatGPT, the study introduces a novel approach to the drug discovery process. This symbiotic partnership between AI and researchers transforms how drug development is approached. Chatbots become facilitators, steering researchers towards innovative methodologies and productive paths for creating effective drug candidates. This research sheds light on the collaborative synergy between human expertise and AI assistance, wherein ChatGPT's cognitive abilities enhance the design and development of potential pharmaceutical solutions. This paper not only

Longer timelines and lower success rates of drug candidates limit the productivity of clinical trials in the pharmaceutical industry. Promising de novo drug design techniques help solve this by exploring a broader chemical space, efficiently generating new molecules, and providing improved therapies. However, optimizing for molecular characteristics found in approved oral drugs remains a challenge, limiting de novo usage. In this work, we propose NovoMol, a novel de novo method using recurrent neural networks to mass-generate drug molecules with high oral bioavailability, increasing clinical trial time efficiency. Molecules were optimized for desirable traits and ranked using the quantitative estimate of drug-likeness (QED). Generated molecules meeting QED's oral bioavailability threshold were used to retrain the neural network, and, after five training cycles, 76% of generated molecules passed this strict threshold and 96% passed the traditionally used Lipinski's Rule of Five. The trained model was then used to generate specific drug candidates for the cancer-related PDGFRα receptor and 44% of generated candidates had better binding affinity than the current state-of-the-art drug,

In our study, we evaluated large language model (LLM) performance on pharmacy licensure-style question-answering tasks and developed an external knowledge integration method to improve accuracy. We benchmarked ten LLMs with varying parameter sizes (8 billion to 70+ billion) using a 141-question pharmacy dataset, measuring baseline accuracy without modification. Baseline performance ranged from 46% to 92%, with GPT-5 (92%) and o3 (89%) achieving the highest scores, while smaller open-source models showed substantially lower performance. We then developed DrugRAG, a three-step retrieval-augmented generation (RAG) pipeline that retrieves structured, evidence-based drug information and augments model prompts with contextual pharmacological evidence, operating externally and requiring no changes to model architecture or parameters. DrugRAG increased accuracy across all five evaluated models, with gains ranging from 7 to 21 percentage points (e.g., Gemma 3 27B: 61.0% to 71%, Llama 3.1 8B: 46% to 67%). McNemar analyses demonstrated statistically significant paired improvements primarily in smaller and mid-sized open-source models. These findings demonstrate that integrating structured ext

The main objective of this paper is to Identify which macroe conomic factors and industrial indexes influenced the total Brazilian banking spread between March 2011 and March 2015. This paper considers subclassification of industrial activities in Brazil. Monthly time series data were used in multivariate linear regression models using Eviews (7.0). Eighteen variables were considered as candidates to be determinants. Variables which positively influenced bank spread are; Default, IPIs (Industrial Production Indexes) for capital goods, intermediate goods, du rable consumer goods, semi-durable and non-durable goods, the Selic, GDP, unemployment rate and EMBI +. Variables which influence negatively are; Consumer and general consumer goods IPIs, IPCA, the balance of the loan portfolio and the retail sales index. A p-value of 05% was considered. The main conclusion of this work is that the progress of industry, job creation and consumption can reduce bank spread. Keywords: Credit. Bank spread. Macroeconomics. Industrial Production Indexes. Finance.

Adolescent girls and young women (AGYW) in sub-Saharan Africa face unique barriers to contraceptive access and lack AGYW-centered contraceptive decision-support resources. To empower AGYW to make informed choices and improve reproductive health outcomes, we developed a tablet-based application to provide contraceptive education and decision-making support in the pharmacy setting - a key source of contraceptive services for AGYW - in Kenya. We conducted workshops with AGYW and pharmacy providers in Kenya to gather app feedback and understand how to integrate the intervention into the pharmacy setting. Our analysis highlights how intermediated interactions - a multiuser, cooperative effort to enable technology use and information access - could inform a successful contraceptive intervention in Kenya. The potential strengths of intermediation in our setting inform implications for technological health interventions in intermediated scenarios in \lrem{LMICs}\ladd{low- and middle-income countries}, including challenges and opportunities for extending impact to different populations and integrating technology into resource-constrained healthcare settings.

Spoken medical dialogue systems are increasingly attracting interest to enhance access to healthcare services and improve quality and traceability of patient care. In this paper, we focus on medical drug prescriptions acquired on smartphones through spoken dialogue. Such systems would facilitate the traceability of care and would free clinicians' time. However, there is a lack of speech corpora to develop such systems since most of the related corpora are in text form and in English. To facilitate the research and development of spoken medical dialogue systems, we present, to the best of our knowledge, the first spoken medical drug prescriptions corpus, named PxSLU. It contains 4 hours of transcribed and annotated dialogues of drug prescriptions in French acquired through an experiment with 55 participants experts and non-experts in prescriptions. We also present some experiments that demonstrate the interest of this corpus for the evaluation and development of medical dialogue systems.

Industrial Edge AI programs often begin with the model and only later confront the platform. That sequencing is attractive because it allows early demonstrations, but it breaks down when the deployment target is an embedded system with long product lifecycles, vendor-specific kernels, heterogeneous accelerators, safety constraints, and nontrivial I/O paths. In that environment, a model is only one component of a larger execution chain that begins at the sensor, traverses the board support package (BSP), and ends in a production service loop. This paper argues that robust Edge AI deployment must be treated as a systems problem rather than a late-stage application packaging exercise. The paper presents a BSP-aware framework for industrial embedded platforms organized around five layers: hardware, BSP/operating-system adaptation, runtime and acceleration, application/inference, and operations/validation. The discussion is grounded in vendor architecture documentation for Android, NXP i.MX, NVIDIA Jetson, ONNX Runtime, and TensorRT, and in systems literature on embedded AI benchmarking, device instability, and heterogeneous edge fleets. The result is a practical framework that connects

This essay is based on the joint project with 111, Inc. The pharmacy e-Commerce business grows rapidly in recent years with the ever-increasing medical demand during the pandemic. A big challenge for online pharmacy platforms is drug product matching. The e-Commerce platform usually collects drug product information from multiple data sources such as the warehouse or retailers. Therefore, the data format is inconsistent, making it hard to identify and match the same drug product. This paper creates an integrated system for matching drug products from two data sources. Besides, the system would correct some inconsistent drug approval numbers based on a Naive-Bayes drug type (Chinese or Non-Chinese Drug) classifier. Our integrated system achieves 98.3% drug matching accuracy, with 99.2% precision and 97.5% recall

Integrating the design and creation of fault identification and diagnostic capabilities into Model-Driven Development methodologies is one approach to enhancing the resilience of Industrial Cyber-Physical Systems. We present a Fault Diagnostic Engine designed to recognise and diagnose faults in IEC 61499 Function Block Applications. Using diagnostic agents that interact directly with the target application, we demonstrate fault monitoring and analysis techniques and as well as failure scenario intervention. By designing and building fault diagnostic resources during early phases of Model-Driven Development, both iterative testing and long-term fault management capabilities can be created. While applying and refining appropriate model artifacts, we demonstrate that the concurrent development of function blocks alongside fault management capabilities is both feasible and worthwhile.

Interoperability across industrial automation systems is a cornerstone of Industry 4.0. To address this need, the OPC Unified Architecture (OPC UA) Publish-Subscribe (PubSub) model offers a promising mechanism for enabling efficient communication among heterogeneous devices. PubSub facilitates resource sharing and communication configuration between devices, but it lacks clear guidelines for mapping diverse industrial traffic types to appropriate PubSub configurations. This gap can lead to misconfigurations that degrade network performance and compromise real-time requirements. This paper proposes a set of guidelines for mapping industrial traffic types, based on their timing and quality-of-service specifications, to OPC UA PubSub configurations. The goal is to ensure predictable communication and support real-time performance in industrial networks. The proposed guidelines are evaluated through an industrial use case that demonstrates the impact of incorrect configuration on latency and throughput. The results underline the importance of traffic-aware PubSub configuration for achieving interoperability in Industry 4.0 systems.

Accurate drug target affinity prediction can improve drug candidate selection, accelerate the drug discovery process, and reduce drug production costs. Previous work focused on traditional fingerprints or used features extracted based on the amino acid sequence in the protein, ignoring its 3D structure which affects its binding affinity. In this work, we propose GraphPrint: a framework for incorporating 3D protein structure features for drug target affinity prediction. We generate graph representations for protein 3D structures using amino acid residue location coordinates and combine them with drug graph representation and traditional features to jointly learn drug target affinity. Our model achieves a mean square error of 0.1378 and a concordance index of 0.8929 on the KIBA dataset and improves over using traditional protein features alone. Our ablation study shows that the 3D protein structure-based features provide information complementary to traditional features.

Metarobotics aims to combine next generation wireless communication, multi-sense immersion, and collective intelligence to provide a pervasive, itinerant, and non-invasive access and interaction with distant robotized applications. Industry and society are expected to benefit from these functionalities. For instance, robot programmers will no longer travel worldwide to plan and test robot motions, even collaboratively. Instead, they will have a personalized access to robots and their environments from anywhere, thus spending more time with family and friends. Students enrolled in robotics courses will be taught under authentic industrial conditions in real-time. This paper describes objectives of Metarobotics in society, industry, and in-between. It identifies and surveys technologies likely to enable their completion and provides an architecture to put forward the interplay of key components of Metarobotics. Potentials for self-determination, self-efficacy, and work-life-flexibility in robotics-related applications in Society 5.0, Industry 4.0, and Industry 5.0 are outlined.

The US Food and Drug Administration (FDA) has been actively promoting the use of real-world data (RWD) in drug development. RWD can generate important real-world evidence reflecting the real-world clinical environment where the treatments are used. Meanwhile, artificial intelligence (AI), especially machine- and deep-learning (ML/DL) methods, have been increasingly used across many stages of the drug development process. Advancements in AI have also provided new strategies to analyze large, multidimensional RWD. Thus, we conducted a rapid review of articles from the past 20 years, to provide an overview of the drug development studies that use both AI and RWD. We found that the most popular applications were adverse event detection, trial recruitment, and drug repurposing. Here, we also discuss current research gaps and future opportunities.

Astrotourism has emerged as a powerful cross sectoral tool to promote science education, sustainable economic development, and cultural exchange. Recognising its potential, the International Astronomical Union's Office of Astronomy for Development (IAU OAD) has developed a suite of openly accessible resources to support individuals and institutions interested in implementing astrotourism initiatives globally. These resources also encourage individuals and existing businesses to broaden their offerings to include activities that use the night sky as a backdrop, such as food experiences, wellness practices, and cultural exploration. This paper offers a comprehensive summary of these resources, available on the OAD's Astrotourism Portal, and situates them within the broader context of astronomy for development work. The paper is targeted at educators, policymakers, tourism operators, grassroots organisers, and entrepreneurs, providing guidance on how they can foster inclusive, locally grounded, and sustainable astrotourism efforts, particularly in underresourced or emerging contexts.

Astronomy, often perceived as a distant or luxury science, holds immense potential as a driver for sustainable local socio-economic development. This paper explores how astronomy can create tangible benefits for communities through education, tourism, technology transfer, and capacity building. Using case studies from South Africa, Chile, Indonesia, and India, we demonstrate how astronomical facilities and initiatives have stimulated local economies, generated employment, supported small enterprises, and enhanced STEM participation, while simultaneously inspiring a sense of shared global heritage. The analysis identifies both successes and challenges, including unequal benefit distribution, limited local ownership, and sustainability gaps once external funding ends. Building on these lessons, we propose a practical framework/guidelines for designing, implementing, and evaluating astronomy-based community initiatives, rooted in participatory engagement and aligned with the UN Sustainable Development Goals (SDGs). This paper positions astronomy as a catalyst for inclusive growth, demonstrating that investment in the cosmos can translate into grounded, measurable benefits for people a

Robots-based smart pharmacies are essential for modern healthcare systems, enabling efficient drug delivery. However, a critical challenge exists in the robotic handling of drugs with varying shapes and overlapping positions, which previous studies have not adequately addressed. To enhance the robotic arm's ability to grasp chaotic, overlapping, and variously shaped drugs, this paper proposed a novel framework combining a multi-stage grasping network with an adaptive robotics mechanism. The framework first preprocessed images using an improved Super-Resolution Convolutional Neural Network (SRCNN) algorithm, and then employed the proposed YOLOv5+E-A-SPPFCSPC+BIFPNC (YOLO-EASB) instance segmentation algorithm for precise drug segmentation. The most suitable drugs for grasping can be determined by assessing the completeness of the segmentation masks. Then, these segmented drugs were processed by our improved Adaptive Feature Fusion and Grasp-Aware Network (IAFFGA-Net) with the optimized loss function, which ensures accurate picking actions even in complex environments. To control the robot grasping, a time-optimal robotic arm trajectory planning algorithm that combines an improved ant